Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2- induced aggregation in cat platelets

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 3, 1998, Pages 233-240

  Ogawa, T ^a   Sugidachi, A ^a   Asai, F ^a   Koike, H ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

5 HT; 5 HT2 receptor; Cat; Ketanserin; Platelet aggregation; TXA2; U 46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; COLLAGEN; INDOMETACIN; KETANSERIN; SEROTONIN; SEROTONIN ANTAGONIST; SULOTROBAN; THROMBOXANE A2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CAT; COLLAGEN METABOLISM; CONCENTRATION RESPONSE; DRUG MECHANISM; FEMALE; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0031831251     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199804000-00003     Document Type: Article

References (31)

1. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500.
2. Mehta JL, Conti CR. Aspirin in myocardial ischemia: why, when, and how much? Clin Cardiol 1989; 12: 179-189.
3. Willerson JT, Golino P, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.
4. Juvela S, Ohman J, Servo A, Heiskanen O, Kaste M. Angiographic vasospasm and release of platelet thromboxane after subarachnoid hemorrhage. Stroke 1991; 22: 451-455.
5. De Clerck F, Loots W, Somers Y, Beetens J, Wouters L, Wymants J, et al. 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. Br J Pharmacol 1990; 99: 631-636.
6. Vanags DM, Rodgers SE, Duncan EM, Lloyd JV, Bochner F. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Br J Pharmacol 1992; 106: 917-923.
7. Baumgartner HR, Born GV. Effects of 5-hydroxytryptamine on platelet aggregation. Nature 1968; 218: 137-141.
8. Tschopp TB. Aggregation of cat platelets in vitro. Thromb Diath Haemorrb 1970; 23: 601-620.
9. De Clerck F, Herman AG. 5-hydroxytryptamine and platelet aggregation. Fed Proc 1983; 42: 228-232.
10. 2-selective agonists on cat platelet aggregation. Life Sci 1987; 41: 1077-1081.
11. 2 receptor antagonist. Arch Int Pharmacodyn Ther 1981; 250: 328-329.
12. 2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb Res 1984; 35: 379-395.
13. 2-receptor sites in the activation of cat platelets. Thromb Res 1984; 33: 305-321.
14. Drummond AH, Gordon JL. Platelet release reaction induced by 5-hydroxytryptamine. J Physiol (Lond) 1974; 240: 39P-40P.
15. 3H]ketanserin. Eur J Pharmacol 1983; 88: 125-130.
16. 2 receptor binding on blood platelets - a peripheral marker for depression? Life Sci 1987; 41: 2485-2492.
17. Gleerup G, Winther K. The effect of aging on human platelet sensitivity to serotonin. Eur J Clin Invest 1988; 18: 504-506.
18. McAdams C, Leonard BE. Changes in platelet aggregatory responses to collagen and 5-hydroxytryptamine in depressed, schizophrenic and manic patients. Int Clin Psychopharmacol 1992; 7: 81-85.
19. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75: 569-576.
20. Barradas MA, Jagroop IA, Mikhailidis DP. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin Chim Acta 1994; 230: 157-167.
21. Krishnamurthi S, Kakkar VV. Studies on the effect of platelet inhibitors on platelet adhesion to collagen and collagen-induced human platelet activation. Thromb Haemost 1985; 53: 337-342.
22. 2 on some isolated smooth muscle preparations. Br J Pharmacol 1981; 73: 773-778.
23. Vanhoutte PM, Van Nueten JM, Symoens J, Janssen PA. Antihypertensive properties of ketanserin (R 41 468). Fed Proc 1983; 42: 182-185.
24. Weiner EJ, Stucchi AF, Foxall TL, Shwaery GT, Yoganathan S, Nicolosi RJ. The effects of doxazosin on platelet aggregation, platelet adhesion and blood coagulation in cynomolgus monkeys. Atherosclerosis 1994; 107: 35-44.
25. 2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther 1983; 227: 327-332.
26. Banga JD, Sixma JJ. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol 1986; 15: 465-492.
27. 2-receptor antagonist. Drugs 1988; 36 (suppl 1): 87-91.
28. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A. 5HT-kinetics and sensitivity of human blood platelets: variations with age, gender and platelet number. Thromb Haemost 1988; 60: 486-490.
29. 2 concentrations after low-dose aspirin. Stroke 1988; 19: 700-703.
30. Beving H, Eksborg S, Malmgren RS, Nordlander R, Ryden L, Olsson P. Inter-individual variations of the effect of low dose aspirin regime on platelet cyclooxygenase activity. Thromb Res 1994; 74: 39-51.
31. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.